Supernus Pharmaceuticals, Inc. Forecast, price target & analysts
Supernus Pharmaceuticals, Inc. Target price 2024 - Analyst rating & recommendation
Supernus Pharmaceuticals, Inc. Classifications & Recommendation:
Supernus Pharmaceuticals, Inc. Target price
| Target price | $40.50 |
| Course | $26.75 |
| Price potential |
51.40%
register free of charge
|
| Number of estimates | 4 |
|
4 Analysts have issued a price target Supernus Pharmaceuticals, Inc. 2025 .
The average Supernus Pharmaceuticals, Inc. target price is $40.50.
This is
51.40%
register free of charge
$43.00
60.75%
register free of charge
$38.00
42.06%
register free of charge
|
|
| A rating was issued by 4 analysts: 3 Analysts recommend Supernus Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst estimates: Analysts believe that the Supernus Pharmaceuticals, Inc. share has an average upside potential 2025 of
51.40%
register free of charge
|
Sales and margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Turnover Million $ | 607.52 | 600.15 |
| 8.95% | 1.21% | |
| EBITDA margin | 16.17% | 19.83% |
| 17.77% | 22.60% | |
| Net margin | 0.18% | 2.29% |
| 97.89% | 1,165.44% |
4 Analysts have issued a sales forecast Supernus Pharmaceuticals, Inc. 2024 . The average Supernus Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth figures:
2 Analysts have issued an Supernus Pharmaceuticals, Inc. EBITDA forecast 2024. The average Supernus Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth figures and future EBITDA margins:
1 Analyst has issued a net profit forecast Supernus Pharmaceuticals, Inc. 2024 . The average Supernus Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth figures and future net margins:
Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Earnings per share $ | 0.02 | 0.25 |
| 98.08% | 1,150.00% | |
| P/E ratio | 107.00 | |
| EV/Sales | 2.02 |
1 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast for earnings per share. The average Supernus Pharmaceuticals, Inc. <a href=/blog/eps>EPS is
This results in the following potential growth figures and future valuations:
Based on analysts' sales estimates for 2024, the Supernus Pharmaceuticals, Inc. share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth figures and future valuations:
Supernus Pharmaceuticals, Inc....
Discover more stocks with a high price target
Register for free
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.
